Startseite Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
Artikel Open Access

Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6

  • Lei Shi , Dehui Zhang und Liangyu Zhang EMAIL logo
Veröffentlicht/Copyright: 13. Juli 2018

Abstract

C22H19NO6, monoclinic, P21/n (no. 14), a = 9.195(4) Å, b = 17.253(5) Å, c = 12.127(5) Å, β = 95.100(16)°, V = 1916.4(12) Å3, Z = 4, Rgt(F) = 0.0405, wRref(F2) = 0.1084, T = 296(2) K.

CCDC no.: 1851952

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.32 × 0.27 × 0.21 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.10 mm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
θmax, completeness:25.0°, >99%
N(hkl)measured, N(hkl)unique, Rint:9483, 3365, 0.045
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2537
N(param)refined:263
Programs:Olex2 [9], SHELX [10], Bruker [11]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
N10.49560(16)0.37245(8)0.40727(11)0.0483(4)
H1A0.4835750.4180000.4337990.058*
H1B0.4546480.3603560.3430600.058*
O10.75159(14)0.40343(6)0.71414(9)0.0498(3)
O20.61551(16)0.46330(7)0.57665(10)0.0599(4)
O30.57946(12)0.25269(6)0.40508(9)0.0421(3)
O40.93243(14)0.13463(7)0.65864(9)0.0536(4)
O50.89809(14)0.09037(7)0.48794(9)0.0511(3)
O60.57235(15)0.23129(8)1.00681(10)0.0620(4)
C10.8455(3)0.46517(13)0.88042(17)0.0817(7)
H1C0.8674320.5142630.9152770.123*
H1D0.7758720.4379070.9203960.123*
H1E0.9333270.4350700.8804840.123*
C20.7839(3)0.47789(11)0.76527(16)0.0636(6)
H2A0.6954430.5085950.7645210.076*
H2B0.8534180.5057490.7244770.076*
C30.66726(19)0.40382(9)0.61672(13)0.0405(4)
C40.65122(18)0.32779(9)0.56748(12)0.0356(4)
C50.57731(18)0.32087(9)0.46539(13)0.0358(4)
C60.68582(17)0.19993(9)0.43730(13)0.0362(4)
C70.75556(17)0.19973(9)0.53939(12)0.0362(4)
C80.72126(18)0.25723(9)0.62582(12)0.0356(4)
H80.8134140.2736070.6658510.043*
C90.86593(19)0.14203(9)0.56841(13)0.0412(4)
C100.82475(19)0.09076(9)0.38317(13)0.0432(4)
C110.71586(18)0.14441(9)0.35368(13)0.0390(4)
C120.6459(2)0.14179(10)0.24681(14)0.0508(5)
H120.5721760.1770900.2256750.061*
C130.6859(2)0.08683(11)0.17235(15)0.0600(5)
H130.6394180.0850910.1010660.072*
C140.7948(2)0.03466(11)0.20428(16)0.0612(6)
H140.821873−0.0019720.1536750.073*
C150.8647(2)0.03555(11)0.30962(16)0.0566(5)
H150.937364−0.0003850.3305960.068*
C160.62571(18)0.22146(9)0.70925(12)0.0378(4)
C170.5164(2)0.16963(10)0.67677(14)0.0481(4)
H170.5013340.1547560.6029270.058*
C180.4288(2)0.13959(11)0.75320(16)0.0570(5)
H180.3551160.1046790.7304200.068*
C190.4498(2)0.16097(11)0.86284(15)0.0546(5)
H190.3905640.1405690.9139510.065*
C200.5589(2)0.21266(10)0.89649(14)0.0460(4)
C210.64754(19)0.24259(10)0.82025(13)0.0435(4)
H210.7219940.2769660.8433600.052*
C220.6966(3)0.27477(14)1.04759(16)0.0734(7)
H22A0.6930730.2839231.1253940.110*
H22B0.7835590.2463541.0356630.110*
H22C0.6971830.3234601.0093230.110*

Source of material

A mixture of 4-hydroxycoumarin (10 mmol), 3-methoxybenzaldehyde (10 mmol), ethyl cyanoacetate (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2–3 h and then cooled to room temperature. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under reduced pressure.

Experimental details

H atoms bonded to C and N atoms were positioned geometrically and refined using a riding model, with C—H = 0.96 Å and N—H = 0.86 Å with Uiso(H) = 1.2 times Ueq(C) and 1.2 times Ueq(N).

Comment

The progress achieved in the synthesis of heterocyclic compounds with biological potential is due to improvement of the methodological study of tested substances [1]. It is known that many coumarin derivatives have biological activity [2]. Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. Symptoms become noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver. Recent research indicated that the use of pyran-based heterocycles is an effective treatment to shrink ovarian cancer and control symptoms [3], [4], [5].

In the title crystal structure (Figure), the dihedral angle of the six-membered ring containing one O atom [C(4), C(5), O(3), C(6), C(7) and C(8)] and the adjacent six-membered carbon ring [C(16)—C(21)] is ∼83°. The bond distances of C—O, C—N and C—C are in their normal ranges and they can be compared with those in previously reported complexes. Comparable with the known similar structures in the reference [6], [7], [8], the most difference is that they own different functional groups. The one -OCH3 group or H atom in the title compound were replaced by other atoms or functional groups such as Cl atom and -CH3 group (Ref. 6), Cl atom (Ref. 7) and -NO2 group (Ref. 8).

References

Song, Y.; Li, N.; Gu, J.; Fu, S.; Peng, Z.; Zhao, C.; Zhang, Y.; Li, X.; Wang, Z.; Li, X.; Liu, G.: β-Hydroxybutyrate induces bovine hepatocyte apoptosis via an ROS-p38 signaling pathway. J. Dairy Sci. 99 (2016) 9184–9198.10.3168/jds.2016-11219Suche in Google Scholar PubMed

Sun, X.; Yuan, X.; Chen, L.; Wang, T.; Wang, Z.; Sun, G.; Li, X.; Li, X.; Liu, G.: Histamine induces bovine rumen epithelial cell inflammatory response via NF-κB pathway. Cell. Physiol. Biochem. 42 (2017) 1109–1119.10.1159/000478765Suche in Google Scholar PubMed

Li, J.; Meng, J.; Qu, D.; Zhang, Z.-D.; Li, F.; Yang, X.-H.; Li, J.-T.; Li, M.-K.: New biscoumarin and dihydropyran derivatives as antimicrobials. Res. Chem. Intermed. 41 (2015) 8257–8267.10.1007/s11164-014-1889-xSuche in Google Scholar

Wu, W.-X.; Zhang, Q.; Hu, X.: New 4-arylpolyhydroquinoline derivatives: inhibiting growth of oral tumor cells. Lat. Am. J. Pharm. 36 (2017) 816–819.Suche in Google Scholar

Shi, D.-Q.; Zhang, S.; Wang, X.-S.; Zhuang, Q.-Y.: Ethyl 2-amino-4-(4-fluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-benzo[b]pyran-3-carboxylate. Acta Crystallogr. E59 (2003) o1501–o1502.10.1107/S1600536803019834Suche in Google Scholar

Srinivasan, L.; Anandalwar, S. M.; Prasad, J. S.; Manvar, D.; Parecha, A.; Shah, A.: Synthesis and crystal structure of 2-amino-4-(3′-chlorophenyl)-3-ethoxycarbonyl-4H-pyrano-[3,2-c]-chromene-5-one. Anal. Sci. 22 (2006) X97–X98.10.2116/analscix.22.x97Suche in Google Scholar

Hu, X.; Song, L.: Ethyl 2-amino-4-(3-chlorophenyl)-5,10-dioxo-5,10-dihydro-4H-benzo[g]-chromene-3-carboxylate. Acta Crystallogr. E65 (2009) o1324–o1324.10.1107/S160053680901753XSuche in Google Scholar PubMed PubMed Central

Wang, X.-S.; Zeng, Z.-S.; Shi, D.-Q.; Chen, H.; Wei, X.-Y.; Zong, Z.-M.: Methyl 2-amino-4-(3-nitrophenyl)-5-oxo-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-carboxylate dimethylformamide solvate. Acta Crystallogr. E60 (2004) o1877–o1879.10.1107/S160053680402358XSuche in Google Scholar

Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 42 (2009) 339–341.10.1107/S0021889808042726Suche in Google Scholar

Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Suche in Google Scholar PubMed PubMed Central

Bruker. SAINT, APEX2 and SADABS. Bruker AXS Inc., Madison, WI, USA (2009).Suche in Google Scholar

Received: 2018-04-10
Accepted: 2018-06-27
Published Online: 2018-07-13
Published in Print: 2018-08-28

©2018 Lei Shi et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2-amino-4-(2,4-dinitrophenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo-pyran, C18H16N4O6
  3. Crystal structure of catena-poly[(μ3-5-carboxy-2-(pyridin-4-yl)benzoato-κ5O,O′:O′′,O′′′:O′′′)(1,10-phenanthroline-κ2N,N′)cadmium(II)], C100H60N12O16Cd4
  4. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C19H18N2O6
  5. Crystal structure of 1-{4-[(2-hydroxy-5-methyl benzylidene)amino]phenyl}ethanone O-ethyl-oxime, C18H20N2O2
  6. Crystal structure of bis{4-methyl-2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O)}copper(II), C36H38CuN4O4
  7. Crystal structure of bis{5-methoxy-2-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O}nickel(II), C34H34N4NiO6
  8. Crystal structure of poly[μ8-3-carboxyphthalat-κ8-O:O1,O1,O1:O2:O3,O3:O4)silver(I)], C9H4Ag2O6
  9. Crystal structure of 2-((E)-((4-((E)-1-(hydroxyimino)ethyl)phenyl)iminio)methyl)-5-methoxyphenolate, C16H16N2O3
  10. Crystal structure of (E)-1-(4-(((E)-2-hydroxy-3-methoxybenzylidene)amino)phenyl)ethan-1-one oxime, C16H16N2O3
  11. The crystal structure of 2-(tert-butyl)-4-chloro-6-phenyl-1,3,5-triazine, C13H14Cl1N3
  12. Crystal structure of (6,6′-(((((2-aminoethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanylylidene))bis(methanylylidene))bis(2,4-dichlorophenolato)-κ6N,N′,N′′,N′′′,O,O′)cadmium(II) – ethanol – water (1/1/1), C22H28CdCl4N4O4
  13. Crystal structure of 6-chloro-N-methylpyrimidin-4-amine, C5H6ClN3
  14. Synthesis and crystal structure of bis{((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)-2-naphtholato-κ2N,O}nickel(II), C40H34N4NiO4
  15. Crystal structure of (E)-2-(4-bromophenyl)ethenesulfonyl fluoride (C8H6BrFO2S)
  16. Synthesis and crystal structure of 2,2′-ethylenedioxybis(benzimide)-2,2′-bis[O-(1-propyloxyamide)]oxime-4,4′,6,6′-tetrachlorodiphenol, C36H34Cl4N4O8
  17. Crystal structure of bis(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)cadmium(II) – methanol (1/1), C26H28N10O4Zn
  18. Crystal structure of diaqua-(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)-bis(nitrato-κ2O,O′)samarium(III), C12H14N7O9Sm
  19. Crystal structure of hexaaqua-{(E)-N′-(1-(pyrazin-2-yl)ethylidene)isonicotinohydrazide-κ3N,N′,O}praseodym(III) trichloride monohydrate, C12H25Cl3N5O8Pr
  20. Crystal structure of methyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C21H22N2O3
  21. Crystal structure of ethyl 2-amino-4-(2-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  22. Crystal structure of 2,12-dibromo-5,15-dihexyl-5,15-dihydrobenzo [1,2-b:5,6-c′]dicarbazole, C38H38Br2N2
  23. Crystal structure of ethyl 2-amino-4-(3-hydroxy-4-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO7
  24. Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-5-oxo-4H,5H-pyrano[3,2-c] chromene-3-carboxylate, C23H21NO5
  25. Crystal structure of 2-hydroxy-N′-(pyrimidin-2-yl)benzohydrazide, C11H10N4O2
  26. Crystal structure of 2-(3,4-dimethylphenyl)-1,8-naphthyridine, C16H14N2
  27. Crystal structure of ethyl 4-(3,4-dimethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C23H29NO3
  28. Crystal structure of ethyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C22H24N2O3
  29. Crystal structure of 7β,9β-dihydroxy-15-oxo-ent-kauran-16-en-19,6β-olide, C20H26O5
  30. Crystal structure of Ent-7β,20-epoxy-kaur-16-en-1β,6α,7α,14α,15α-pentaol-20-one, C20H30O8
  31. Crystal structure of 1,4-bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydro-1H,3H-furo[3,4-c]furan-3a(4H)-yl acetate, C22H20O8
  32. Crystal structure of methyl 2-((4-((2-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)methyl) benzoate, C18H16N4O5
  33. Crystal structure of diaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O)zinc(II), C12H14N4O10Zn
  34. Hydrothemal synthesis and crystal structure of triaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O1O)manganese(II), C12H16N4O11Mn
  35. Redetermination of methyl 4-(4-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22ClNO3
  36. Crystal structure of bis{1-[(benzotriazol-1-yl)methyl]-1-H-1,3-(2-methyl-imdazol)-κN}-dithiocyano-κN-zinc(II) C24H22N12S2Zn
  37. Crystal structure of (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl furan-2-carboxylate, C10H7FN2O5
  38. Crystal structure of bis(η6-cymene)-tri-μ2-chlorido-ruthenium(II) tetrafluoroborate, C20H28BCl3F4Ru2
  39. Crystal structure of 3,6-diphenyl-7H-[1,2,4]-triazolo[3,4-b][1,3,4]thiadiazine, C16H12N4S
  40. Synthesis and crystal structure of 1,3-bis[(3,4-dicyano)phenoxy]-4,6-dinitro-benzene, C22H8N6O6
  41. Crystal structure of ethyl 2-amino-4-(2,6-dichlorophenyl)-7-methyl-5-oxo-4H,5H-pyrano [4,3-b]pyran-3-carboxylate, C18H15Cl2NO5
  42. Crystal structure of poly[μ3-hydroxy-(μ5-(5-(2-carboxylatophenoxy)isophthalato-κ6O1:O2:O3:O4:O5,O6)-(μ2-1,4-di(1H-imidazol-1-yl)butane-κ2N:N′)dicobalt(II)] hemihydrate, C25H22Co2N4O8.5
  43. Crystal structure of methyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H22BrNO3
  44. Crystal structure of 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate trihydrate, C35H33NO12
  45. Crystal structure of 2,5-bis(4-(10H-phenothiazin-10-yl)phenyl)-1,3,4-oxadiazole, C38H24N4OS2
  46. The crystal structure of (E)-2-(4-hydroxyphenyl)-5-(prop-1-en-1-yl)benzofuran-3-carbaldehyde, C18H14O3
  47. Crystal structure of bis{5H-dibenzo[c,f][1,5]oxabismocin-12(7H)-yl} carbonate, C29H24O5Bi2
  48. Crystal structure of ethyl-5-formyl-3,4-dimethylpyrrole-2-carboxylate — N-(5-ethoxycarbonyl-3,4-dimethylpyrrole)-2-methylene-5-nitrobenzene-1,2-diamine (1:1), C26H31N5O7
  49. Crystal structure of (E)-2-(1-((2-aminophenyl)imino)ethyl)-6-bromo-4-chlorophenol, C14H12BrClN2O
  50. Crystal structure of (Z)-2-(4-chlorophenyl)-4-(furan-2-yl(phenylamino)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one, C21H16ClN3O2
  51. Crystal structure of N2,N4-dibutyl-6-chloro-N2,N4-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4-diamine, C31H58ClN7 – Important intermediate of Chimassorb 119 synthesis
  52. Crystal structure of 1-(5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone oxime, C17H15BrN2O2
  53. Crystal structure of poly-{diaqua-bis[(μ2-3-nitrobenzenesulfonylglycine-κ3N:O:O′)(4,4′-bipyridine)manganese(II)]}-dimethylformamide (1/1), C39H35Mn2N9O15S2
  54. Crystal structure of 4-(dimethylamino)-1-(prop-2-yn-1-yl)pyridin-1-ium perchlorate, C10H13ClN2O4
  55. Crystal structure of 2-amino-5-oxo-4-(4-chloro-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C15H11ClN2O2
  56. Crystal structure of triaqua-(pyridine-2,6-dicarboxylato-κ3O,N,O′)cobalt(II) – 6-phenyl-1,3,5-triazine-2,4-diamine (1/1), C16H18CoN6O7
  57. Crystal structure of ethyl 2-amino-4-(3-cyanophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C21H22N2O4
  58. Crystal structure of 2-(4-chloro-2,6-dinitrophenyl)-1-(4-chloro-3-nitrophenyl)diazene 1-oxide, C12H5Cl2N5O7
  59. Crystal structure of 3,4-dimethyl-2,6-dinitrophenol, C8H8N2O5
  60. Crystal structure of 1,2-dimethyl-3,5-dinitrobenzene, C8H8N2O4
  61. Crystal structure of ethyl 4-(3-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C21H24ClNO3
  62. Crystal structure of N-(4-chlorophenyl)-2-(2,6-dichlorophenyl)acetamide, C14H10Cl3NO
  63. Crystal structure of 2-amino-4-(4-fluorophenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2c] chromene, C19H11FN2O3
  64. The crystal structure of (4-nitrophenyl) (5-ferrocenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl) methanone, C21H12F3FeN3O3
  65. Crystal structure of 5,5′-((3-hydroxy-4-methoxyphenyl)methylene)bis(1,3-diethyl-6-hydroxy-2-thioxo-2,3-dihydropyrimidin-4(1H)-one), C24H30N4O6S2
  66. Crystal structure of (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-ethyl-5-(1-hydroxy-2-((R)-3-hydroxypyrrolidin-1-yl)ethoxy)-4,7,9,12-tetramethyldecahydro-4,9a-propanocyclopenta[8]annulene-3,8-diol – a pleuromutilin derivative, C26H41NO5
  67. Crystal structure of bis(μ2-3-formyl-5-methoxy-2-oxidobenzoato-κ3O,O′:O′)-hexapyridine-dicadmium(II) – pyridine (1/1), C53H47Cd2N7O10
  68. Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  69. Crystal structure of methyl 4-(3,5-ditrifluoromethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate — water (2/1), C22H21F6NO3
  70. Crystal structure of 2-(4-bromophenyl)-2,3-dihydro-1H-perimidine, C17H13BrN2
  71. Crystal structure of (5-ethyl-2-(4-methoxyphenyl)-1,3-dioxan-5-yl)methanol, C14H20O4
  72. Crystal structure of (E)-N-(4-bromo-2-(1-(hydroxyimino)ethyl)phenyl)benzamide, C15H13BrN2O2
  73. Crystal structure of caffeinium triiodide – caffeine (1/1), C16H21I3N8O4
  74. Crystal structure of methyl 2-methyl-4-(3-methoxyphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C19H21NO4
  75. Crystal structure of (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-phenylprop-2-en-1-one, C23H28O2
  76. Crystal structure of 1,4-bis(2-azidoethyl)piperazine-1,4-diium dichloride, C8H18N8Cl2
  77. The crystal structure of dichlorido-(1,3-bis(2,6-dimethylphenyl)-1H-imidazol-2(3H)-ylidene)-(morpholine-κ1N)palladium(II), C23H29Cl2N3OPd(II)
  78. The crystal structure of 1-((5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-yl)methyl)-1,3-diphenylurea, C24H21ClN4O
  79. Crystal structure of 6-(2-bromoacetamido)tetrahydro-2H-pyran-2,3,4,5-Tetrayl tetraacetate, C16H22BrNO10
  80. Crystal structure of 5-methylpyrazine-2-carbohydrazide, C6H8N4O
  81. Crystal structure of catena-poly[(μ2-5-(tert-butyl)isophthalato-κ4O,O′:O′′,O′′′)(-4′-(pyridin-4-yl)-2,2′:6′,2′′-terpyridine-κ3N,N′,N′′)manganese(II)], C32H28N4O5Mn
Heruntergeladen am 17.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2018-0110/html
Button zum nach oben scrollen